Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
INSM > SEC Filings for INSM > Form 8-K on 1-Apr-2013All Recent SEC Filings

Show all filings for INSMED INC | Request a Trial to NEW EDGAR Online Pro

Form 8-K for INSMED INC


Regulation FD Disclosure, Financial Statements and Exhibits

Item 7.01. Regulation FD Disclosure.

Insmed Appoints Chief Commercial Officer

Insmed Incorporated (the "Company") announced today that it appointed Matthew Pauls as its Chief Commercial Officer. In this newly created position, Mr. Pauls reports to Will Lewis, President and Chief Executive Officer, and has full global commercial responsibility for ARIKACEŽ, liposomal amikacin for inhalation, which is under development to treat Pseudomonas aeruginosa lung infections in cystic fibrosis (CF) patients and patients with non-tuberculous mycobacteria (NTM) lung infections. Mr. Pauls brings to the Company more than 20 years of experience in the pharmaceutical industry, including senior-level leadership roles in global marketing, sales, reimbursement, new product launches and commercial operations at leading pharmaceutical companies including Shire Pharmaceuticals, Bristol-Myers Squibb and Johnson & Johnson.

In connection with the appointment of Mr. Pauls, the Company made inducement grants of stock options to Mr. Pauls to purchase a total of 300,000 shares of the Company's common stock. A copy of the press release issued by the Company with respect to such grants is filed as Exhibit 99.1 and is incorporated herein by reference.

Update as to Nasdaq Matters

In the Company's Annual Report on Form 10-K for the year ended December 31, 2012 (the "Form 10-K"), the Company disclosed that it had inadvertently exceeded the annual per-person sub-limits applicable under its Amended and Restated 2000 Stock Incentive Plan, as amended, in connection with certain equity compensation awards previously made by the Company and that the Company had notified Nasdaq of these excess grants. The Company has been telephonically advised by Nasdaq that the Nasdaq staff does not intend to cite the Company for a violation of Nasdaq's listing rules in connection with the excess grants. For additional information, please see the discussion contained under Item 1A in the Form 10-K under the caption "Risk Factors - Risks Related to our Common Stock and Listing on the Nasdaq Capital Market - If we fail to meet the continued listing requirements of the Nasdaq Capital Market, our common stock may be delisted from the Nasdaq Capital Market, which may cause the value of an investment in our common stock to decrease."

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description
99.1 Press Release issued by Insmed Incorporated on April 1, 2013

  Add INSM to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for INSM - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now

Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.